Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study

REFERENCES

• Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibi-tors: a systematic review. AIDS. 2009;23:279–291
   PubMed Web of Science ®Google Scholar
• Vernazza P, Daneel S, Schiffer V, et al. The role of com-partment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21:1309–1315.
   PubMed Web of Science ®Google Scholar
• Garvey LJ, Yerrakalva D, Winston A. 2009. Correla-tions between computerized battery testing and a memory questionnaire for identification of neurocog-nitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy. AIDS Res Hum Retroviruses. 2009;25:765–769.
   Web of Science ®Google Scholar
• Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45:174–182.
   PubMed Web of Science ®Google Scholar
• Dawes S, Suarez P, Casey CY, Cherner M, Marcotte TD, Letendre S, Grant I, Heaton RK. Variable patterns of neu-ropsychological performance in HIV-1 infection. J Clin Exp NeuropsychoL 2008;30:613–626.
   PubMed Web of Science ®Google Scholar
• Canestri A, Lescure X, Jaureguiberry S, et al. 2009. HIV-related meningoencephalitis in patients with optimally sup-pressed plasma HIV RNA receiving stable ART. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada. Abstract 484a.
   Google Scholar
• Munoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses. 2008;24:1301–1307.
   PubMed Web of Science ®Google Scholar
• Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27:11–17.
   PubMed Web of Science ®Google Scholar
• Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359–1366.
   PubMed Web of Science ®Google Scholar
• Letendre SL, van den Brande G, Hermes A, et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis. 2007;45.
   Web of Science ®Google Scholar
• Gutmann C, Opravil M, Yerly S, et al; Swiss HIV Cohort Study. Low-nadir CD4 count predicts failure of mono-therapy maintenance with ritonavir-boosted lopinavir: results after premature termination of a randomized study due to unexpectedly high failure rate in the monotherapy arm. Presented at: 16th Conference on Retroviruses and Opportunistic Infections,; 2009; Montreal, Canada. Abstract 578.
   Google Scholar
• Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslen M. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses. 2009;25:457–461.
   PubMed Web of Science ®Google Scholar
• Letendre S, Rossi S, Best B, et al; HNRC Group. Darunavir concentrations in CSF exceed the median inhibitory con-centration. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Fransisco, California. Abstract 45.
   Google Scholar
• Arribas J, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir monotherapy shows non-inferior effi-cacy to standard HAART, for patients with HIV RNA < 50 copies/mL at baseline. Presented at: International AIDS Society Meeting; 2009; Cape Town, South Africa. Abstract TuAb 106.
   Google Scholar
• Cella DF, McCain NU, Peterman AH, Mo F, Wolen D. Devel-opment and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAH) quality of life instrument. Qua/ Life Res. 1996;5:450–463.
   PubMed Web of Science ®Google Scholar
• Robinson-Papp J, Byrd D, Mindt MR, Oden NU, Simpson DM, Morgello S. Motor function and human immuno-deficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort. Arch Neurol. 2008;65:1096–1101.
   PubMed Web of Science ®Google Scholar
• Njamnshi AK, Djientcheu Vde P, Fonsah JY, Yepnjio FN, Njamnshi DM, Muna WE. The International HIV Demen-tia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaounde-Cameroon. J Acquir Immune Defic Syndr. 2008;49:393–397.
   PubMed Web of Science ®Google Scholar
• Sprinz E, Bay MB, Lazzaretti RK, Jeffman MW, Mattevi VS. Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil. HIVMed. 2008;9:270–276.
   PubMed Web of Science ®Google Scholar
• Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009; Cape Town, South Africa. Abstract WELBB102.
   Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Brigid E, et al. Low atazanavir con-centrations in cerebrospinal fluid. AIDS. 2009;23:83–87.
   PubMed Web of Science ®Google Scholar
• Baum MK, Jayaweera DT, Duan R, et al. Quality of life, symptomatology and healthcare utilization in HIV/ HCV co-infected drug users in Miami. J Addict Dis. 2008;27:37–48.
   PubMed Web of Science ®Google Scholar
• Winston A, Garvey L, Scotney E, et al. Does acute hepa-titis C infection affect the central nervous system in HIV-1 infected individuals? [published ahead of print September 25,2009]. J Viral Hepat.
   PubMed Web of Science ®Google Scholar
• Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, Brew BJ, Dore GJ. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med. 2007;8:520–528.
   PubMed Web of Science ®Google Scholar